Skip to main content
. Author manuscript; available in PMC: 2015 Jul 29.
Published in final edited form as: J Viral Hepat. 2014 Jul 10;22(2):175–183. doi: 10.1111/jvh.12278

Fig. 2.

Fig. 2

Cost-effectiveness acceptability curve (a1) Telaprevir IL-28B-guided therapy (quality-adjusted life years – QALYs as outcome), (a2) Telaprevir IL-28B-guided therapy (LYs as outcome), (b1) Boceprevir rapid virologic response (RVR)-guided therapy (QALYs as outcome) and (b2) Boceprevir RVR-guided therapy (LYs as outcome).